Sinolink: Hydrogen Energy and Fuel Cells Face Overall Pressure in 2024, Gradually Building a Closed-loop Business Model by 2025.
Hydrogen energy and fuel cell manufacturing are currently two main lines of development.
Sinolink released a research report stating that in December, FCV saw negative growth for the first time, while the total installed power continued to increase throughout the year, indicating a significant trend towards high-power in the industry. 2025 will be a significant year for the settlement of hydrogen energy medium and long-term planning, as the hydrogen energy and fuel cell industry will enter a period of accelerated deployment, with fuel cell vehicles and green hydrogen projects ramping up. Hydrogen energy and fuel cell manufacturing are currently the industry's main focus.
Key points from Sinolink's report are as follows:
- FCV saw negative growth for the first time in December, while the total installed power continued to grow, indicating a significant trend towards high-quality development in the industry.
- Heavy-duty trucks dominate the market, with Zhengzhou Yutong leading in terms of FCV deployments.
- Demonstration cities continue to drive production and sales, with Henan and Hebei leading the way towards an increase in 2025.
- Global FCV production and sales data from Japan, South Korea, and the United States were also highlighted.
- The report also emphasized the upcoming surge in green hydrogen projects and electrolyzer tenders in 2025, which will drive demand for hydrogen production equipment.
The report concluded with investment recommendations for specific companies in the industry and outlined potential risks related to policy changes, slow development of hydrogen refueling stations, and unexpected challenges in reducing the cost of hydrogen or deploying green hydrogen projects.
Related Articles

Tianjin Tianyao Pharmaceuticals(600488.SH) subsidiary received drug GMP compliance inspection results.

Zhejiang Shapuaisi Pharmaceutical (603168.SH) signed a technology transfer contract with Wenzhou Medical University Eye Hospital and others.

Open source Securities: Non-GAAP net profit of the 2025 annual report of securities firms meets expectations, and wealth management and overseas business are highlights.
Tianjin Tianyao Pharmaceuticals(600488.SH) subsidiary received drug GMP compliance inspection results.

Zhejiang Shapuaisi Pharmaceutical (603168.SH) signed a technology transfer contract with Wenzhou Medical University Eye Hospital and others.

Open source Securities: Non-GAAP net profit of the 2025 annual report of securities firms meets expectations, and wealth management and overseas business are highlights.






